Addyi vs Low-Dose Testosterone for Women: Comparing the Two and the Case for Combining Them

What Is Addyi and Who Is It Actually For?

Addyi (flibanserin) is the only FDA-approved oral drug for HSDD in premenopausal women. It works centrally, not hormonally. The drug increases dopamine and norepinephrine while decreasing serotonin activity in prefrontal brain circuits that govern sexual motivation. Think of it as shifting the neurochemical balance away from inhibition and toward desire.

The FDA approved flibanserin in August 2015 after two earlier rejections. The approval came with a Risk Evaluation and Mitigation Strategy (REMS) because of a serious drug-alcohol interaction: combining the two can cause severe hypotension and syncope.

Who the approval covers

Addyi's labeling specifies premenopausal women with acquired, generalized HSDD, meaning the low desire is not situational, not caused by relationship problems alone, and is genuinely distressing to you. That distress criterion matters. A woman with low desire who is entirely comfortable with it does not meet the diagnosis.

What the BEGONIA trial actually found

The BEGONIA trial (J Sex Med, 2014) was a phase III, double-blind, placebo-controlled study in 1,850 premenopausal women with HSDD. Women taking flibanserin 100 mg nightly reported approximately 0.5 additional satisfying sexual events per 28 days compared with placebo, a statistically significant but modest absolute difference. Female Sexual Function Index desire scores improved by roughly 1.0 point more than placebo. Dizziness, somnolence, nausea, and fatigue were the most common side effects, each affecting 8 to 13 percent of the active-drug group.

That absolute effect size gets criticized frequently, but it reflects the heterogeneity of HSDD, not necessarily a drug failure. Some women respond substantially; others do not respond at all.

What Addyi does not do

It does not raise testosterone. It does not address vaginal dryness or genitourinary syndrome of menopause (GSM). It has no direct effect on ovulation or the menstrual cycle, though the somnolence and nausea can, in practice, affect your daily quality of life enough to disrupt mood and indirectly affect desire further. That is a real clinical consideration.

What Low-Dose Testosterone Does in Women

Testosterone is not just a male hormone. Women produce testosterone in the ovaries and adrenal glands throughout their reproductive years, and levels drop progressively from the mid-20s onward. By the time a woman reaches natural menopause, circulating testosterone is roughly half what it was at age 20.

Low-dose testosterone for women is used off-label in the United States because no product is FDA-approved for female use. Clinicians prescribe compounded transdermal gels or creams, or male-approved products (such as 1% testosterone gel) applied at one-tenth the male dose, targeting a free testosterone level in the upper quartile of the normal premenopausal female range (generally 0.9 to 3.0 ng/dL free testosterone, though lab assays vary).

The 2019 Global Consensus Statement

The International Society for the Study of Women's Sexual Health (ISSWSH) and 10 co-endorsing organizations published a Global Consensus Statement in 2019 recommending testosterone therapy for postmenopausal women with HSDD when other causes have been excluded. The statement explicitly states: "There is insufficient evidence to support use in premenopausal women." The evidence base is simply thinner there, and that honesty matters when you are making a treatment decision.

For postmenopausal women, however, the consensus reviewed data from multiple randomized controlled trials and found a clinically meaningful benefit in sexual desire, arousal, and satisfying sexual events with transdermal testosterone at physiological doses. The 300 mcg/day transdermal patch (the Intrinsa patch, never approved in the U.S. But studied extensively in Europe) was the best-characterized regimen in the trials reviewed.

How testosterone differs from Addyi mechanistically

Testosterone works peripherally and centrally. Peripherally, it increases genital blood flow, clitoral sensitivity, and vaginal lubrication to some degree. Centrally, androgens act on hypothalamic and limbic receptors that influence sexual motivation and reward. This is a fundamentally different mechanism from flibanserin's serotonin-dopamine rebalancing in the prefrontal cortex.

Because the mechanisms are distinct, there is a pharmacological rationale for combining them. Whether that translates into additive clinical benefit is a separate question, covered below.

Life-stage specifics for testosterone

| Life stage | Testosterone status | Evidence for use | |---|---|---| | Reproductive years (20s-30s) | Gradual natural decline begins | Very limited RCT data; Global Consensus says insufficient evidence | | Perimenopause | Estrogen drops faster than testosterone but both fall | Small observational studies only | | Surgical menopause | Abrupt drop in both estrogen and testosterone | Strongest individual-patient rationale; some RCT support | | Natural postmenopause | Testosterone approximately 50% of peak | Best RCT evidence base; Global Consensus endorses use |

Addyi vs Low-Dose Testosterone: A Direct Comparison

The table below organizes the comparison by the clinical variables that actually matter when you and your clinician are deciding between them, or considering both.

| Factor | Addyi (flibanserin) | Low-dose testosterone | |---|---|---| | FDA approval | Yes, for premenopausal HSDD | No FDA-approved female product | | Mechanism | Central: serotonin down, dopamine up | Peripheral + central: androgen receptor agonism | | Route | Oral, nightly | Transdermal (gel, cream, patch) | | Onset | 4 to 8 weeks | 8 to 12 weeks | | Life stage with best evidence | Premenopausal | Postmenopausal | | Satisfying sexual events improvement | ~0.5 per 28 days vs placebo (BEGONIA) | ~0.7 to 1.2 per 28 days vs placebo (pooled patch trials) | | Major safety concern | Hypotension with alcohol or CYP3A4 inhibitors | Acne, hirsutism at supraphysiological doses; long-term cardiovascular data limited in women | | Contraindicated in pregnancy | Yes | Yes | | Requires monitoring labs | No (unless on interacting drugs) | Yes: total and free testosterone, SHBG at baseline and 3-6 months | | Cost without insurance | Approximately $800-$1,000/month | Varies: $30-$150/month compounded |

Addyi's specific drug interactions in women

The CYP3A4 interaction deserves its own paragraph because it catches many women off guard. Fluconazole (a very commonly prescribed antifungal for vaginal yeast infections), oral contraceptive pills containing ethinyl estradiol, and grapefruit juice are all moderate-to-strong CYP3A4 inhibitors. Taking any of these with Addyi can raise flibanserin plasma levels four to seven-fold and dramatically increase hypotension risk. If you take a combined oral contraceptive, your prescriber needs to know before starting Addyi.

Testosterone monitoring is not optional

Supraphysiological testosterone levels in women are associated with acne, hirsutism, voice changes, and clitoral enlargement, some of which may be irreversible. The Global Consensus (2019) recommends measuring total testosterone and sex hormone-binding globulin (SHBG) at baseline, at three months, and then every six months during therapy. Dose should be adjusted to keep free testosterone within the normal premenopausal female range.

The Case for Combining Flibanserin and Testosterone

No large randomized controlled trial has tested flibanserin plus testosterone head-to-head against either agent alone in women. That evidence gap is real, and any clinician who tells you otherwise is overstating what exists. What follows is the mechanistic and clinical rationale that informs current off-label combined use, along with the honest limits of that rationale.

Why the mechanisms argue for combination

Flibanserin acts on motivational circuitry in the prefrontal cortex, specifically on 5-HT1A and 5-HT2A receptors, as well as dopamine D4 receptors. It does not restore androgen-mediated genital sensitivity, arousal, or hypothalamic drive. Testosterone acts on androgen receptors in genital tissue, the hypothalamus, and limbic structures. A woman who has both neurotransmitter dysregulation (the central inhibition Addyi targets) and androgen deficiency (the peripheral and hypothalamic deficit testosterone targets) has two separate problems. Treating only one may produce a partial response.

This mechanistic rationale is analogous to combining two antihypertensives with different mechanisms. The logic is sound. The outcomes data in women are not yet there.

When a clinician might suggest both

Clinicians who specialize in female sexual medicine describe a pattern: a woman tried Addyi for three to six months, saw partial improvement in desire but not arousal or genital sensation, and also had lab values showing testosterone in the low-normal or below-normal range with appropriate symptoms. In that scenario, adding low-dose testosterone addresses the androgen component that Addyi cannot touch.

The reverse scenario also exists: a postmenopausal woman on testosterone for 12 weeks with improvement in arousal but persistent lack of spontaneous desire. Some clinicians with specific expertise in sexual medicine consider adding flibanserin off-label in postmenopausal women in this situation, though the FDA approval does not cover that population.

The honest risks of combining

1. No combination RCT data in women. Safety signals from combination use come from case series and clinical experience, not controlled trials.
2. Additive CNS depression is theoretically possible, given flibanserin's somnolence burden and the fact that androgens can have sedating effects at high levels.
3. Cost and adherence burden: managing both a nightly oral drug (Addyi) and a daily transdermal application (testosterone) is a real-world adherence challenge.
4. Monitoring complexity: you need both CYP3A4 medication review for Addyi and periodic androgen labs for testosterone.

Dr. Rachel Goldberg, reviewing this article, notes: "In my practice I consider combination therapy only after each agent has been trialed individually and the patient has incomplete response to monotherapy. The mechanistic rationale is legitimate, but women deserve to know that we are working from first principles, not from combination trial data."

Switching From Addyi to Low-Dose Testosterone

If Addyi has not worked for you after eight weeks at the full 100 mg nightly dose, switching to testosterone is a reasonable next step, particularly if you are perimenopausal or postmenopausal. The switch rationale depends on which aspect of HSDD predominates.

When switching makes sense

• You had side effects from Addyi (dizziness, somnolence, nausea) that limited your ability to use it consistently.
• You take medications that interact with CYP3A4 and cannot safely use Addyi.
• You are postmenopausal, where the Global Consensus (2019) supports testosterone as a first-line option specifically.
• Your lab work shows free testosterone below the lower quartile of the normal female range.
• Your symptoms include impaired genital sensation or arousal, not just low desire, because Addyi has no peripheral genital mechanism.

When staying on Addyi or adding to it makes sense

• You are premenopausal, your testosterone levels are normal, and the deficit appears to be purely central (loss of spontaneous desire without arousal impairment or low-normal androgens).
• You had a partial but real response to Addyi and your clinician has identified a possible androgen component based on labs and symptoms.

Practical logistics of switching

Addyi does not require tapering. You can stop it and begin testosterone immediately, though the testosterone will take eight to twelve weeks to produce measurable clinical effect. Set a realistic expectation before starting: the most common reason women abandon testosterone prematurely is expecting a response in four weeks.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Both drugs are contraindicated in pregnancy. This is not negotiable.

Addyi in pregnancy and lactation

Flibanserin is Pregnancy Category X equivalent under the current labeling system, meaning animal studies show fetal harm and the risks in pregnant women clearly outweigh any benefit. There are no adequate human pregnancy data. If you are using Addyi, you must use effective contraception. Flibanserin itself does not reduce contraceptive efficacy, but many hormonal contraceptives are CYP3A4 inhibitors that raise flibanserin levels and increase hypotension risk. A non-hormonal IUD or barrier method plus condom avoids this interaction entirely. Lactation transfer has not been studied; the drug should not be used while breastfeeding.

Testosterone in pregnancy and lactation

Testosterone is classified as contraindicated in pregnancy (previously Pregnancy Category X) because androgens cause virilization of a female fetus. This is a well-documented teratogenic risk. Women of reproductive age who use testosterone must use reliable contraception. Testosterone is not recommended during lactation because transfer into breast milk has not been adequately studied and androgen exposure to an infant carries theoretical developmental risk.

Perimenopause-specific note

Many perimenopausal women are not reliably ovulating but are not fully menopausal. Conception is still possible. Contraception remains necessary until 12 consecutive months without a menstrual period confirm natural menopause. Do not assume irregular cycles mean you cannot conceive.

Who This Approach Is Right For, and Who It Is Not

Best candidates for Addyi

• Premenopausal women (under 50 approximately) with acquired HSDD causing genuine distress.
• Normal hormone levels on testing (ruling out testosterone deficiency as the primary driver).
• No regular alcohol use (the alcohol interaction is not a theoretical risk; it is a clinically serious one).
• Not taking antifungals, certain antidepressants, or hormonal contraceptives that inhibit CYP3A4.

Best candidates for low-dose testosterone

• Postmenopausal women with HSDD, per the Global Consensus 2019.
• Women with surgical menopause (bilateral oophorectomy), who experience an abrupt androgen drop that natural menopause does not fully replicate.
• Perimenopausal or premenopausal women with documented low-normal free testosterone plus sexual symptoms, understanding that evidence here is weaker.
• Women for whom the physical components of sexual dysfunction (arousal, genital sensation, lubrication) are more prominent than the purely motivational/desire component.

Who should avoid or be cautious with both

• Women actively trying to conceive: both drugs are contraindicated.
• Women with active liver disease: flibanserin is hepatically metabolized; hepatic impairment substantially increases drug exposure.
• Women with androgen-sensitive conditions (certain ovarian or adrenal tumors, or a history of androgen-sensitive malignancy): testosterone is contraindicated.
• Women with PCOS: testosterone levels in PCOS are often already elevated. Adding exogenous testosterone in this population risks worsening hyperandrogenism, acne, and metabolic parameters. Addyi has not been studied specifically in PCOS, but HSDD does occur in women with PCOS and can be addressed with appropriate evaluation and informed consent about the limits of available data.

The Evidence Gap Women Deserve to Know About

Women were historically underrepresented in cardiovascular and metabolic drug trials, and sexual medicine is no exception. The trials underpinning Addyi's approval enrolled only premenopausal women. The testosterone trials reviewed in the Global Consensus enrolled predominantly postmenopausal women, with far fewer premenopausal participants. There is almost no head-to-head trial data comparing these two agents directly. The combination has never been tested in a published RCT.

A 2019 analysis published in JAMA Internal Medicine noted that HSDD affects an estimated 8 to 10 percent of premenopausal women and up to 12 to 14 percent of postmenopausal women, yet the treatment pipeline remains thin relative to the condition's prevalence. That gap between burden and evidence should inform how you weigh the options. None of this means treatment is futile. It means the conversation with your clinician should be specific, honest, and based on your individual labs, symptoms, and life stage, not on marketing.

Practical Monitoring Summary

If you are on Addyi, your clinician should review your medication list at every visit for CYP3A4 interactions, particularly if you develop a vaginal infection requiring fluconazole. A one-time fluconazole dose is not an emergency, but your prescriber should know and you should not take both on the same day if avoidable.

If you are on testosterone, baseline and follow-up labs should include: total testosterone, free testosterone (calculated or dialysis method), SHBG, and hematocrit (androgens can stimulate erythropoiesis). A lipid panel at baseline is reasonable given the limited long-term cardiovascular data in women.

If you are on both, build a monitoring schedule with your clinician before starting. The combination is not reckless if managed carefully, but it requires more active follow-up than either agent alone.